Inactive Instrument

Other languages aTyr Pharma Inc Nasdaq

Equities

US0021201035

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

ATyr Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14
ATyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis	Feb. 21
ATyr Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect?? Study of Efzofitimod in Patients with Ssc-Ild	23-10-31
Top Premarket Gainers	23-10-04
Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes	23-09-11
ATyr Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
ATyr Pharma's Efzofitimod Gets Orphan Drug Label from European Commission for Systemic Sclerosis	23-06-22
Insider Buy: aTYR Pharma	23-05-11
ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09
ATyr Pharma Publishes First Peer-Reviewed Paper on Efzofitimod as Potential Therapy for Pulmonary Sarcoidosis	23-03-30
ATyr Pharma, Inc. to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate Atyr0101 At Keystone Symposia on Fibrosis Pathogenesis and Resolution	23-03-21
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-09
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-09
ATyr Pharma, Inc. Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application	23-03-01
ATyr Pharma to Obtain $10 Million in Milestone Payment After Partner Starts Dosing Patients in Lung Disease Study in Japan	23-02-06
ATyr Pharma Secures Patent Allowance for Efzofitimod Combination Treatment in EU	23-01-19
ATyr Pharma's Efzofitimod Gets Orphan Drug Designation from European Commission for Sarcoidosis Treatment	23-01-18
Atyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment	22-12-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages aTyr Pharma Inc Nasdaq

Equities

US0021201035

Other languages

Filters